Rezdiffra (Resmetirom) Safety in Older Adults (50 to 64): What the Evidence Shows

Why the 50-to-64 Age Window Matters for Resmetirom

Adults between 50 and 64 represent the demographic most likely to carry a diagnosis of MASH with clinically significant fibrosis. This is the decade when cumulative metabolic insult from insulin resistance, dyslipidemia, and visceral adiposity converges with early fibrotic progression. MAESTRO-NASH enrolled patients with a mean age of approximately 56 years, placing a large share of the efficacy and safety data squarely within this bracket [1].

Overlapping Metabolic Risk

By age 50, most patients prescribed resmetirom already take at least one cardiovascular or metabolic medication. The 2023 AACE MASH clinical practice guideline identifies this age group as carrying overlapping risk: type 2 diabetes prevalence exceeds 20%, hypertension prevalence surpasses 45%, and statin use is common [2]. Each of these factors alters how clinicians should frame resmetirom safety, not because the drug itself is riskier in this group, but because the background medication list is longer and the margin for drug-drug interactions narrows.

Hormonal Transitions and Liver Biology

Women in perimenopause lose the hepatoprotective effect of estradiol, which accelerates MASH progression between ages 50 and 60. Men in the same window experience declining testosterone levels that correlate with increased visceral fat and hepatic steatosis. The Endocrine Society's 2023 guideline on testosterone therapy notes that andropause-associated metabolic syndrome amplifies hepatic lipotoxicity [3]. Resmetirom's THR-β mechanism does not directly interact with sex hormone pathways, but patients in hormonal transition may already be on hormone replacement therapy, which adds another layer to the polypharmacy assessment.

MAESTRO-NASH Trial: Safety Findings Relevant to Ages 50 to 64

The MAESTRO-NASH phase 3 trial (N=966 randomized) provides the key safety dataset for resmetirom. Patients received 80 mg, 100 mg, or placebo once daily [1]. The trial's inclusion criteria required biopsy-confirmed MASH with fibrosis stage F1B through F3, and metabolic comorbidities were common across all arms.

Adverse Event Profile

At 52 weeks, gastrointestinal events dominated the safety signal. Diarrhea occurred in 26.7% of the 80 mg group versus 14.2% of placebo. Nausea affected 22.2% versus 11.7%. Most GI events were mild to moderate and resolved within the first 12 weeks of dosing [1].

Serious adverse events occurred at similar rates across groups (approximately 11 to 12%), with no clustering around hepatic decompensation events. Drug discontinuation due to adverse events was 5.8% in the 80 mg arm and 2.5% in the placebo arm [1].

Subgroup Analyses by Age

The published MAESTRO-NASH data show consistent efficacy across prespecified age subgroups (above and below 57 years). The FDA's clinical review for Rezdiffra documents that safety event rates did not differ significantly by age stratum [4]. Older patients within the trial did not experience disproportionate hepatotoxicity, thyroid-related events, or cardiovascular events compared to younger enrollees.

What Wasn't Studied

MAESTRO-NASH excluded patients with decompensated cirrhosis (Child-Pugh B or C), active hepatocellular carcinoma, and uncontrolled thyroid disease. Patients over 75 were underrepresented. The 52-week primary endpoint captures medium-term safety, but the long-term profile in the 50-to-64 cohort will depend on Part 2 data extending to 54 months, expected in 2027.

Thyroid Function Monitoring

Resmetirom is a selective THR-β agonist, meaning it activates the beta isoform of the thyroid hormone receptor expressed predominantly in the liver. The prescribing information warns against use in patients with uncontrolled thyroid disease and requires baseline and periodic TSH and free T4 measurement [4].

Why This Matters After 50

Subclinical hypothyroidism prevalence rises with age. The NHANES dataset analyzed by the NIH showed that TSH elevation above 4.5 mIU/L affects roughly 10% of women and 4% of men by age 60 [5]. A patient starting resmetirom with an unrecognized TSH of 6.0 mIU/L could experience a shift in thyroid axis signaling that escapes detection without systematic monitoring.

Recommended Monitoring Schedule

Check TSH and free T4 at baseline, at 4 weeks, at 12 weeks, and every 6 months thereafter. If TSH rises above the upper limit of normal or free T4 falls below range, hold resmetirom and reassess thyroid status before restarting. The Endocrine Society's 2014 hypothyroidism guideline recommends that levothyroxine dose adjustments, if needed, should precede reinitiation of any THR-β agonist [6].

Hepatic Safety and Liver Monitoring

The core rationale for resmetirom is hepatic. Patients aged 50 to 64 with MASH and F2-F3 fibrosis are at measurable risk of progression to cirrhosis within the next decade. The global burden analysis published in The Lancet Gastroenterology estimated that 20 to 25% of MASH patients with F3 fibrosis progress to cirrhosis within 7 years [7].

Liver Enzyme Elevations

In MAESTRO-NASH, ALT elevations above 3x the upper limit of normal occurred in 2 to 3% of resmetirom-treated patients, comparable to placebo [1]. This is a reassuring signal for a drug that targets liver biology directly. ALT and AST should still be checked at baseline, month 3, month 6, and annually, because the patients most likely to receive this drug already have elevated baseline enzymes.

Interpreting Liver Enzymes on Treatment

Resmetirom reduces hepatic fat, which often produces a paradoxical initial ALT decrease. A rising ALT after an initial decline should trigger clinical evaluation rather than being attributed to drug effect. The AASLD practice guidance for MASH recommends that any ALT increase above 5x ULN warrants drug discontinuation and hepatology referral [8].

"We expect ALT to trend downward in the first 12 to 24 weeks. If it reverses course, that warrants investigation for an alternative etiology, not a wait-and-see approach," stated Dr. Arun Sanyal, lead investigator of MAESTRO-NASH, in his presentation at AASLD's The Liver Meeting 2023.

Cardiovascular Considerations

Adults aged 50 to 64 with MASH carry a cardiovascular mortality risk that exceeds their liver-related mortality risk. The European Heart Journal meta-analysis by Targher et al. demonstrated that NAFLD/MASH independently increases cardiovascular event risk by approximately 45% [9]. Any drug prescribed to this population must be evaluated through a cardiovascular lens.

Lipid Effects

Resmetirom reduced LDL cholesterol by 13 to 16% and triglycerides by 20 to 25% versus placebo in MAESTRO-NASH at 52 weeks [1]. Apolipoprotein B and lipoprotein(a) also declined. These are favorable directional signals.

For patients already on statins, the LDL reduction from resmetirom is additive. However, resmetirom is a CYP2C8 substrate and may affect statin metabolism. The prescribing information advises monitoring for statin-related myopathy when co-prescribing [4].

Blood Pressure and Heart Rate

No clinically meaningful changes in blood pressure or heart rate were observed in MAESTRO-NASH [1]. Unlike triiodothyronine (T3), which acts on THR-α in the heart and can increase heart rate, resmetirom's selectivity for THR-β spares the cardiac α-receptor. This selectivity is the pharmacologic basis for its cardiovascular neutrality.

MACE Outcomes

MAESTRO-NASH was not powered to detect differences in major adverse cardiovascular events (MACE). A dedicated cardiovascular outcomes trial, MAESTRO-OUTCOMES, is ongoing and will provide definitive data. Until then, the lipid-lowering signal is directionally encouraging but should not be treated as a substitute for established CV risk-reduction therapies.

Polypharmacy and Drug Interactions

The average adult aged 50 to 64 with MASH takes 4 to 6 medications. Resmetirom's interaction profile is narrow but clinically relevant.

CYP2C8 Pathway

Resmetirom is primarily metabolized by CYP2C8. Strong CYP2C8 inhibitors (gemfibrozil is the most clinically relevant) are contraindicated. The FDA drug interaction guidance classifies gemfibrozil as a strong CYP2C8 inhibitor that could increase resmetirom exposure by several-fold [10]. Since gemfibrozil is sometimes prescribed for hypertriglyceridemia in MASH patients, this contraindication has practical consequences. Fenofibrate is a safer fibrate alternative if triglyceride-lowering is needed alongside resmetirom.

Statin Co-administration

Resmetirom may increase exposure to certain statins processed through overlapping hepatic pathways. The prescribing information recommends using the lowest effective statin dose and monitoring for myalgia or CK elevation [4]. Rosuvastatin and pitavastatin, which rely less on CYP-mediated metabolism, may carry lower interaction risk, though formal interaction studies for all statins have not been published.

Thyroid Hormone Replacement

Patients on levothyroxine require TSH re-evaluation after resmetirom initiation. Resmetirom's THR-β activation in the liver can alter the feedback loop indirectly. "Patients stable on levothyroxine for years may need dose re-titration within the first 3 months of resmetirom therapy," noted the AACE/ACE guidance panel in their 2024 MASH management update [2].

Common Co-medications to Review

| Medication Class | Concern | Action | |---|---|---| | Gemfibrozil | Strong CYP2C8 inhibitor | Contraindicated with resmetirom | | Statins | Possible increased statin exposure | Use lowest effective dose; monitor CK | | Levothyroxine | TSH shift after THR-β activation | Recheck TSH at 4 and 12 weeks | | Metformin | No known interaction | Continue; no adjustment required | | GLP-1 receptor agonists | Additive GI effects (nausea, diarrhea) | Stagger initiation; monitor GI tolerance | | Pioglitazone (CYP2C8 substrate) | Competitive CYP2C8 metabolism | Monitor for pioglitazone-related edema |

Managing Gastrointestinal Side Effects

GI symptoms are the most frequent reason patients consider stopping resmetirom. In MAESTRO-NASH, diarrhea affected over a quarter of the 80 mg arm [1]. For adults aged 50 to 64, who may already contend with irritable bowel changes, gastroesophageal reflux, or GLP-1-agonist-induced nausea, this side effect requires active management.

Onset and Duration

Most GI adverse events occurred within the first 4 to 8 weeks and resolved without dose modification. Fewer than 4% of patients discontinued due to GI intolerance [1].

Practical Strategies

Take resmetirom with food. The prescribing information specifies administration with food to improve absorption and reduce GI irritation [4]. Patients already on a GLP-1 agonist such as semaglutide or tirzepatide should expect additive nausea risk. Starting both agents simultaneously is not advisable. Space the initiation of resmetirom at least 4 weeks after GLP-1 dose stabilization, or vice versa.

Special Populations Within the 50 to 64 Window

Patients with Type 2 Diabetes

Approximately 60% of MAESTRO-NASH participants had type 2 diabetes [1]. Resmetirom does not directly affect glucose homeostasis, but hepatic fat reduction may improve insulin sensitivity over time. No dose adjustment is needed for diabetic patients. Metformin and SGLT2 inhibitors can be continued without modification.

Patients with Chronic Kidney Disease (Stages 1 to 3)

MAESTRO-NASH included patients with eGFR above 30 mL/min. No pharmacokinetic studies have established dose adjustment for CKD stages 4 or 5. For patients with mild-to-moderate CKD (stages 1 to 3), which is common in the 50-to-64 MASH population, standard dosing applies [4].

Patients on Anticoagulants

Resmetirom has no established interaction with warfarin or direct oral anticoagulants. The prescribing information does not list anticoagulants as interacting medications [4]. Standard INR monitoring for warfarin users is sufficient.

Weight-Based Dosing and the 50-to-64 Demographic

Resmetirom is dosed by body weight. Patients weighing less than 100 kg receive 80 mg once daily. Patients at or above 100 kg receive 100 mg once daily [4]. There is no age-based adjustment.

The 50-to-64 age group spans a wide BMI range. MAESTRO-NASH enrolled patients with a mean BMI of approximately 36 kg/m², and efficacy was consistent across weight strata [1]. Clinicians should use actual body weight at initiation and reassess if significant weight change occurs during concurrent GLP-1 agonist therapy.

When to Reassess or Discontinue

The accelerated FDA approval of resmetirom requires confirmatory data from the ongoing MAESTRO-NASH Part 2. The prescribing information does not specify a mandatory treatment duration, but the clinical trial demonstrated benefit at 52 weeks with histologic endpoints [1].

Reassess at 12 months with non-invasive fibrosis markers (FIB-4, ELF score, or vibration-controlled transient elastography). The Baveno VII consensus endorses serial elastography for monitoring fibrosis trajectory in treated MASH patients [11]. If liver stiffness has not improved or has worsened, discuss discontinuation and alternative management with the patient and their hepatologist.

Discontinue resmetirom immediately for: ALT above 5x ULN with symptoms, new decompensation events (ascites, variceal bleeding, hepatic encephalopathy), or confirmed pregnancy [4].